Neidio i'r prif gynnwy

Canser a Gwaed

 Allogeneic Haematopoietic Stem Cell Transplant (HSCT) for people of all ages with Sickle Cell Disease (SCD), Commissioning Policiy (CP224), March 2025.pdf (PDF, 595Kb)
 Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours, Policy Position Statement (PPS315), November 2025 (PDF, 423Kb)
 Autologous haematopoietic stem cell transplantation for people aged 18 years and over with previously treated relapsing multiple sclerosis, Commissioning Policy (CP247), November 2024.pdf (PDF, 523Kb)
 Bleeding Disorders (All Ages), Service Specification (CP77), June 2022.pdf (PDF, 343Kb)
 Brachytherapy for the treatment of gynaecological malignancies for people aged 18 years and above, Commissioning Policy (CP75), July 2024.pdf (PDF, 440Kb)
 Brachytherapy for the treatment of localised prostate cancer, Commissioning Policy (CP01), November 2024.pdf (PDF, 540Kb)
 Cannabidiol for treating seizures caused by tuberous sclerosis complex in people aged 2 years and above (PP272), December 2026.pdf (PDF, 249Kb)
 Chimeric Antigen Receptor T Cell (CAR T) Therapy, Gilead Axicabtagene Ciloleucel (Yescarta®), Service Specification (CP175), March 2019.pdf (PDF, 514Kb)
 Chimeric Antigen Receptor T Cell (CAR T) Therapy, Novartis Tisagenlecleucel (Kymriah ®) Service Specification, (CP176), March 2019.pdf (PDF, 571Kb)
 Chimeric Antigen Receptor T Cell (CAR T) Therapy, Policy Position Statement (PP185), April 2023.pdf (PDF, 254Kb)
 Emicizumab as prophylaxis in people with congenital haemophilia A with factor VIII inhibitors (all ages), Policy Position Statement (PPS167), September 2025.pdf (PDF, 459Kb)
 Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors, Policy Position Statement, (PP189), November 2023.pdf (PDF, 288Kb)
 Services for Children with Cancer, Service Specification (SS86), December 2024.pdf (PDF, 509Kb)
 Sickle Cell Disorders, Thalassaemia Disorders and other rare hereditary anaemias all ages, Service Specification (CP179), December 2020.pdf (PDF, 453Kb)
 Soft tissue sarcoma, Service Specification (SS149), November 2025 (PDF, 556Kb)
 Specialised Immunology, Service Specification (SS78), October 2024.pdf (PDF, 615Kb)
 Stereotactic ablative body radiotherapy (SABR) for patients aged 18 years old and above (PP278), Policy Position Statement, August 2026.pdf (PDF, 511Kb)
 Stereotactic ablative body radiotherapy (SABR) for patients aged 18 years old and above with (LANPC) (PP280), Policy Position Statement, August 2026.pdf (PDF, 371Kb)
 Stereotactic Ablative Body Radiotherapy (SABR) for patients with metachronous extracranial oligometastic cancer (all ages), Commissioning Policy (CP121), December 2024.pdf (PDF, 551Kb)
 Stereotactic Ablative Body Radiotherapy (SABR) for the management of Non-Small Cell Lung Cancer in people aged 18 years and above, Commissioning Policy (CP76), June 2023.pdf (PDF, 525Kb)